Trial Profile
A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 21 Feb 2023 Planned End Date changed from 31 May 2023 to 31 Dec 2024.
- 21 Feb 2023 Planned primary completion date changed from 31 May 2023 to 31 Dec 2024.
- 06 Apr 2022 Planned End Date changed from 1 May 2021 to 31 May 2023.